Eli Lilly and Company (NYSE:LLY) Shares Sold by Norden Group LLC

Norden Group LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,682 shares of the company’s stock after selling 35 shares during the quarter. Norden Group LLC’s holdings in Eli Lilly and Company were worth $980,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Penobscot Investment Management Company Inc. grew its stake in shares of Eli Lilly and Company by 9.5% in the fourth quarter. Penobscot Investment Management Company Inc. now owns 6,380 shares of the company’s stock valued at $3,719,000 after buying an additional 552 shares in the last quarter. Duff & Phelps Investment Management Co. lifted its stake in Eli Lilly and Company by 1.0% in the fourth quarter. Duff & Phelps Investment Management Co. now owns 8,904 shares of the company’s stock worth $5,190,000 after acquiring an additional 90 shares during the last quarter. Field & Main Bank lifted its position in shares of Eli Lilly and Company by 9.5% during the 4th quarter. Field & Main Bank now owns 7,722 shares of the company’s stock worth $4,501,000 after purchasing an additional 668 shares during the last quarter. Kestra Private Wealth Services LLC raised its stake in Eli Lilly and Company by 3.2% in the fourth quarter. Kestra Private Wealth Services LLC now owns 29,472 shares of the company’s stock valued at $17,180,000 after buying an additional 908 shares in the last quarter. Finally, Ledyard National Bank lifted its stake in Eli Lilly and Company by 0.6% during the fourth quarter. Ledyard National Bank now owns 3,998 shares of the company’s stock worth $2,331,000 after purchasing an additional 22 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 6.0 %

Shares of NYSE LLY traded up $44.10 during mid-day trading on Tuesday, reaching $781.30. The company had a trading volume of 5,419,168 shares, compared to its average volume of 3,044,902. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78. The stock’s 50 day moving average is $760.89 and its 200-day moving average is $668.00. The stock has a market capitalization of $742.36 billion, a PE ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 earnings per share. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $731.55.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.